Results 201 to 210 of about 60,678 (260)

Cytomegalovirus Reactivation During Therapy for Pediatric Acute Lymphoblastic Leukemia. [PDF]

J Med Virol
Melavarige Venkatagiri A, Reddy N, Chandwani R, Shekar N, Perampalli Manjunath S, Abdu Rahiman E, Mukhopadhyay C, Bhat Kalya V.   +7 more
europepmc   +1 more source

Anti‐BCMA immunotherapies deplete plasmacytoid dendritic cells and impair antiviral immunity in multiple myeloma

HemaSphere, Volume 10, Issue 8, August 2026.
Ondrej Venglar, Eva Radova, Maxima Warmuzova, Daniel Bilek, Marketa Kudelkova, Katerina Jasinkova, Ludmila Muronova, Lucie Broskevicova, Veronika Kapustova, Jan Vrana, Tereza Novakova, Katerina Karasova, Michaela Hornakova, Tereza Popkova, Jana Mihalyova, Hana Plonkova, Michal Simicek, Jakub Radocha, Tereza Sevcikova, David Zihala, Juli Bago, Roman Hajek, Tomas Jelinek   +22 more
wiley   +1 more source

Probable sepsis‐associated encephalopathy as a component of multiple organ dysfunction syndrome in a cat with pyothorax

Australian Veterinary Journal, Volume 104, Issue 8, Page 523-531, August 2026.
A 2‐year‐old male neutered domestic shorthair cat with bacterial pyothorax was referred to a tertiary hospital for treatment of sepsis. He met criteria for multiple organ dysfunction syndrome and developed new‐onset neurological dysfunction subsequent to the development of sepsis.
CC Chan, CR Sharp, CJ Boyd
wiley   +1 more source

Diagnosis and management of neutropenia in adults: Expert guidance

British Journal of Haematology, Volume 209, Issue 2, Page 432-440, August 2026.
Severe neutropenia can result from decreased production of neutrophil precursors in the bone marrow, as in the case of severe congenital neutropenia, or from increased utilization of neutrophils or their accelerated destruction as for drug‐induced neutropenia or autoimmune neutropenia. Severe chronic neutropenia increases susceptibility to bacterial or
Karl Welte, Cornelia Zeidler, Julia Skokowa, Sabine Mellor‐Heineke, Audrey Anna Bolyard, David Dale   +5 more
wiley   +1 more source

Mutational Signature‐Based Biomarker for Phase II Trial of Olaparib Maintenance in Advanced High‐Grade Ovarian Cancer

Cancer Science, Volume 117, Issue 8, Page 2259-2273, August 2026.
A whole‐exome sequencing–based mutational signature biomarker (MSBM) identified an HRD‐enriched population in advanced ovarian cancer. In a phase II trial, olaparib maintenance suggested clinically meaningful PFS benefit without bevacizumab, supporting MSBM as a complementary HRD assessment approach.
Katsutoshi Oda, Daisuke Shintani, Akira Nishijima, Mayuyo Mori, Kazuyoshi Kato, Shoji Nagao, Noriomi Matsumura, Masahiro Kagabu, Masataka Takenaka, Kosuke Yoshihara, Yosuke Konno, Junzo Hamanishi, Sho Sato, Shiro Takamatsu, Keiko Ueda, Kosuke Kashiwabara, Takashi Aoki, Kunihiro Nishimura, Kenji Tatsuno, Hiroyuki Aburatani, Kosei Hasegawa   +20 more
wiley   +1 more source

Safety and Effectiveness of Dimethyl Fumarate in Japanese Patients With Multiple Sclerosis: Subgroup Analysis of Older Patients and Patients Switching From Fingolimod or Natalizumab Using 2‐Year Post‐Marketing Surveillance Data

Clinical and Experimental Neuroimmunology, Volume 17, Issue 3, August 2026.
In a 2‐year post‐marketing surveillance of Japanese patients with multiple sclerosis, dimethyl fumarate (DMF) showed manageable safety, with no new concerns identified; lymphocyte decreases were more frequent in older patients and those switching from fingolimod.
Ichiro Nakashima, Toshiyuki Fukazawa, Kazumasa Yokoyama, Takashi Yamamura, Hirofumi Ochi, Michihiro Kanda, Yayoi Sato, Ryusuke Sato, Haruki Makioka, Aya Tsuchiya, Takahiko Saida   +10 more
wiley   +1 more source

Unveiling Gut Homeostasis Disruption in Sepsis: Towards an Integrated Mechanistic and Translational Roadmap

Cell Proliferation, Volume 59, Issue 8, August 2026.
Elucidating the contribution of gut‐organ axes will provide new insights for developing combined therapeutic strategies against sepsis‐associated multiple organ dysfunction. ABSTRACT Sepsis, a life‐threatening clinical syndrome precipitated by a maladaptive host response to infection, is associated with substantial morbidity and high mortality rates ...
Yichen Bao, Lin Qi, Guijun Zou, Xingpeng Yang, Yizhao Ma, Zhifu Li, Xiaohui Du, Pengyue Zhao   +7 more
wiley   +1 more source

The Efficacy and Safety of Teplizumab in the Treatment of Stage 3 Type 1 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. [PDF]

Diabetes Metab Syndr Obes
Sun Q, Zhao G.
europepmc   +1 more source

Paediatric‐onset autoimmune cytopenia: How can we reduce the long‐term mortality?

British Journal of Haematology, Volume 209, Issue 2, Page 825-829, August 2026.
Nathalie Aladjidi, Thierry Leblanc, Helder Fernandes, Capucine Picard, Jacinta Bustamante, Frédéric Rieux‐Laucat, Mathieu Fusaro, Maud Tusseau, Charlotte Durand‐Teyssier, Emma Cohendy, Jérôme Granel, Stéphane Ducassou, Agathe Escudier, Despina Moshous, Marc Michel, Bertrand Godeau, Sébastien Héritier, Mony Fahd, Brigitte Bader‐Meunier, Alain Fischer, Guy Leverger, All collaborators from the French Paediatric Haemato‐Immunologic CEREVANCE Network   +21 more
wiley   +1 more source

X-linked SEPTIN6-related congenital neutropenia and B cell deficiency. [PDF]

J Hum Immun
Gunderman LM, Petrovic A, Lundgren I, Chisholm KM, Bohling SD, Fromm JR, Ferrannini A, Torgerson TR, Dutmer CM, Hsieh EWY, Mohamad SF, Williams DA, Allenspach EJ.   +12 more
europepmc   +1 more source